Serum albumin-adjusted glycated albumin is an adequate indicator of glycemic control in patients with Cushing's syndrome

Clinical Biochemistry

Volumn 47, Issue 18, 2014, Pages 279-282

  Kitamura, Tetsuhiro ^a   Otsuki, Michio ^a   Tamada, Daisuke ^a   Tabuchi, Yukiko ^a   Mukai, Kosuke ^a   Morita, Shinya ^b   Kasayama, Soji ^b   Bando, Yukihiro ^c   Shimomura, Iichiro ^a   Koga, Masafumi ^d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nissay Hospital   (Japan)

^c FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^d Department of Internal Medicine Kawanishi City Hospital   (Japan)

Author keywords

Albumin; Cushing's syndrome; Glucocorticoid; Glycated albumin; HbA1c

Indexed keywords

GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; SERUM ALBUMIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN;

ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADULT; BLOOD; BODY MASS; COMPLICATION; METABOLISM; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CUSHING SYNDROME; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; SERUM ALBUMIN;

EID: 84921272974     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.09.007     Document Type: Article

References (33)

1. Cohen M.P. Nonenzymatic glycation: a central mechanism in diabetic microvasculopathy?. J Diabet Complications 1998, 2:214-217.
2. Koenig R.J., Peterson C.M., Jones R.L., Saudek C., Lehrman M., Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976, 295:417-420.
3. Bunn H.F., Gabbay K.H., Gallop P.M. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978, 20:21-27.
4. Jeffcoate S.L. Diabetes control and complications: the role of glycated haemoglobin, 25years on. Diabet Med 2004, 21:657-665.
5. Bry L., Chen P.C., Sacks D.B. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001, 47:153-163.
6. Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta 2014, 433:96-104.
7. Okada T., Nakao T., Matsumoto H., Nagaoka Y., Tomaru R., Iwasawa H., et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med 2011, 50:23-29.
8. Koga M., Murai J., Saito H., Matsumoto S., Kasayama S. Effect of thyroid hormone on serum glycated albumin levels: study on non-diabetic subjects. Diabetes Res Clin Pract 2009, 84:163-167.
9. Koga M., Kasayama S., Kanehara H., Bando Y. CLD (chronic liver disease)-HbA1c as a novel indicator for estimation of mean plasma glucose in the patients with chronic liver disease. Diabetes Res Clin Pract 2008, 81:258-262.
10. Simmons P.S., Miles J.M., Gerich J.E., Haymond M.W. Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range. J Clin Invest 1984, 73:412-420.
11. Burt M.G., Gibney J., Ho K.K. Protein metabolism in glucocorticoid excess: study in Cushing's syndrome and the effect of treatment. Am J Physiol Endocrinol Metab 2007, 292:E1426-E1432.
12. Kitamura T., Otsuki M., Tamada D., Tabuchi Y., Mukai K., Morita S., et al. Glycated albumin is set lower in relation to plasma glucose levels in patients with Cushing's syndrome. Clin Chim Acta 2013, 424:164-167.
13. Nieman L.K., Biller B.M., Findling J.W., Newell-Price J., Savage M.O., Stewart P.M., et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:1526-1540.
14. Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G.P., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593-6602.
15. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479-484.
16. Mancini T., Kola B., Mantero F., Boscaro M., Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004, 61:768-777.
17. Putignano P., Kaltsas G.A., Korbonits M., Jenkins P.J., Monson J.P., Besser G.M., et al. Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment. J Clin Endocrinol Metab 2000, 85:3309-3312.
18. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society (JDS) International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int 2012, 3:8-10.
19. Kouzuma T., Usami T., Yamakoshi M., Takahashi M., Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta 2002, 324:61-71.
20. Rohlfing C.L., Wiedmeyer H.M., Little R.R., England J.D., Tennill A., Goldstein D.E. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care 2002, 25:275-278.
21. Hirata T., Saisho Y., Morimoto J., Kasayama S., Koga M., Maruyama T. The ratio of glycated albumin to HbA1c is correlated with diabetes duration according to decreases in insulin secretion in patients with autoimmune type 1 diabetes and type 2 diabetes. J Genet Syndr Gene Ther 2013, 4:168.
22. Griffin P., Wild A.E. Effect of dexamethasone on Fc gamma receptor expression in foetal and neonatal rat gut. Experientia 1988, 44:242-245.
23. Kim K.J., Fandy T.E., Lee V.H., Ann D.K., Borok Z., Crandall E.D. Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 2004, 287:L616-L622.
24. 1C reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia 2011, 54:2247-2253.
25. Suzuki S., Koga M., Takahashi H., Matsuo K., Tanahashi Y., Azuma H. Glycated albumin in patients with neonatal diabetes mellitus is apparently low in relation to glycemia compared with that in patients with type 1 diabetes mellitus. Horm Res Paediatr 2012, 77:273-276.
26. Suzuki S., Koga M., Niizeki N., Furuya A., Takahashi H., Matsuo K., et al. Glycated albumin is lower in infants than in adults and correlated with both age and serum albumin. Pediatr Diabetes 2013, 14:25-30.
27. Suzuki S., Koga M., Niizeki N., Furuya A., Matsuo K., Tanahashi Y. et al. Age-adjusted glycated albumin: a more robust parameter to establish glycaemic control in neonatal diabetes mellitus. Ann Clin Biochem 2014, 51:602-605.
28. 1C ratio with hepatic function tests in patients with chronic liver disease. Ann Clin Biochem 2009, 46:368-372.
29. Koga M. Glycated albumin and 1,5-anhydroglucitol as alternative markers of glycemia. Adv Clin Chem 2014, 64:269-301.
30. Tsutsumi C., Imagawa A., Onishi M., Sano H., Nakagawa S., Murase-Mishiba Y., et al. Glycated albumin as a useful clinical biomarker for glycemic variability in type 1 diabetes assessed by continuous glucose monitoring. Diabetol Int 2013, 4:156-159.
31. Burt M.G., Roberts G.W., Aguilar-Loza N.R., Frith P., Stranks S.N. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011, 96:1789-1796.
32. Burt M.G., Willenberg V.M., Petersons C.J., Smith M.D., Ahern M.J., Stranks S.N. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford) 2012, 51:1112-1119.
33. Yamanouchi T., Sekino N., Yoshimura T., Kawasaki T., Koshibu E., Inoue T., et al. Acute glucosuria after continuous glucocorticoid loading in the rat in vivo. Eur J Pharmacol 1998, 341:257-263.